Calcitonin: Uses, Mechanism, and Side Effects

For people managing bone disorders tied to calcium regulation, calcitonin is one of the older hormone-based options still in clinical use. It has decades of marketed history and a defined, if limited, role alongside newer bone therapies.

Key takeaways

• Calcitonin salmon is approved for Paget's disease of bone, hypercalcemia, and postmenopausal osteoporosis.
• It works as a calcitonin receptor agonist, acting mainly on bone with additional effects on the kidney and gut.
• Fracture reduction efficacy has not been demonstrated for its osteoporosis indication.
• More than 470 registered trials reference calcitonin-related research.
• The most frequently reported adverse events include nausea, falls, and musculoskeletal pain.

What Calcitonin Is

Calcitonin salmon belongs to the calcitonin drug class and acts as a calcitonin receptor agonist. It is marketed under the brand name Calcitonin Salmon. Its primary actions occur in bone, though it also has recognized effects on the kidneys and gastrointestinal tract. Compared with calcitonins from mammalian sources, it is described as more potent per milligram and longer acting.

What Calcitonin Is Approved For

Calcitonin salmon is indicated for symptomatic Paget's disease of bone in patients with moderate to severe, polyostotic disease when alternative treatments are not suitable. It is also approved to treat hypercalcemia and to treat postmenopausal osteoporosis when other treatments are not appropriate. The label notes that fracture reduction has not been demonstrated for the osteoporosis use. Because of a possible link between malignancy and calcitonin salmon use, the label advises periodically reassessing whether continued therapy is needed. No boxed warning is present on the label.

What the Evidence Shows

More than 470 trials in the clinical trials registry reference calcitonin. Among the sampled records, one study examined calcitonin gene-related peptide expression in human periodontal ligament tissue, and another investigated pro-calcitonin as a marker of ischemia during complicated coronary interventions; both illustrate the breadth of calcitonin-related research beyond its approved bone indications.

Reported Side Effects

Adverse event reports associated with calcitonin salmon most commonly involve nausea (254 reports) alongside reports of the drug being ineffective (249). Falls (221), general pain (213), arthralgia (189), dizziness (184), headache (178), and back pain (173) were also frequently reported. These figures reflect submitted reports, not confirmed incidence or proven causation, and should be interpreted with that limitation in mind.